|Mr. Michael J. Farrell||Chief Exec. Officer and Director||2M||2.07M||45|
|Mr. Robert A. Douglas||Pres and Chief Operating Officer||1.54M||1.48M||57|
|Mr. Brett A. Sandercock||Chief Financial Officer and Principal Accounting Officer||756.84k||N/A||50|
|Mr. David B. Pendarvis||Chief Admin. Officer, Global Gen. Counsel and Interim Pres of EMEA & Japan||940.42k||1.75M||58|
|Mr. James Hollingshead||Pres of Americas||884.13k||N/A||54|
ResMed Inc. designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. Its portfolio of products include devices, such as air flow generators, ventilators, and oxygen concentrators; diagnostic products; mask systems; headgear and other accessories; dental devices; portable oxygen concentrators; and cloud-based software informatics solutions. The company also produces continuous positive airway pressure, variable positive airway pressure, and AutoSet systems for the titration and treatment of sleep disordered breathing (SDB). In addition, it offers data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 100 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
ResMed Inc.’s ISS Governance QualityScore as of June 2, 2017 is 2. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 5.